Prognostic implications of comorbidity patterns in critically ill COVID-19 patients: A multicenter, observational study.
COVID-19
Critical Care
Prognosis
Journal
The Lancet regional health. Europe
ISSN: 2666-7762
Titre abrégé: Lancet Reg Health Eur
Pays: England
ID NLM: 101777707
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
entrez:
3
6
2022
pubmed:
4
6
2022
medline:
4
6
2022
Statut:
epublish
Résumé
The clinical heterogeneity of COVID-19 suggests the existence of different phenotypes with prognostic implications. We aimed to analyze comorbidity patterns in critically ill COVID-19 patients and assess their impact on in-hospital outcomes, response to treatment and sequelae. Multicenter prospective/retrospective observational study in intensive care units of 55 Spanish hospitals. 5866 PCR-confirmed COVID-19 patients had comorbidities recorded at hospital admission; clinical and biological parameters, in-hospital procedures and complications throughout the stay; and, clinical complications, persistent symptoms and sequelae at 3 and 6 months. Latent class analysis identified 3 phenotypes using training and test subcohorts: low-morbidity (n=3385; 58%), younger and with few comorbidities; high-morbidity (n=2074; 35%), with high comorbid burden; and renal-morbidity (n=407; 7%), with chronic kidney disease (CKD), high comorbidity burden and the worst oxygenation profile. Renal-morbidity and high-morbidity had more in-hospital complications and higher mortality risk than low-morbidity (adjusted HR (95% CI): 1.57 (1.34-1.84) and 1.16 (1.05-1.28), respectively). Corticosteroids, but not tocilizumab, were associated with lower mortality risk (HR (95% CI) 0.76 (0.63-0.93)), especially in renal-morbidity and high-morbidity. Renal-morbidity and high-morbidity showed the worst lung function throughout the follow-up, with renal-morbidity having the highest risk of infectious complications (6%), emergency visits (29%) or hospital readmissions (14%) at 6 months (p<0.01). Comorbidity-based phenotypes were identified and associated with different expression of in-hospital complications, mortality, treatment response, and sequelae, with CKD playing a major role. This could help clinicians in day-to-day decision making including the management of post-discharge COVID-19 sequelae. ISCIII, UNESPA, CIBERES, FEDER, ESF.
Sections du résumé
Background
UNASSIGNED
The clinical heterogeneity of COVID-19 suggests the existence of different phenotypes with prognostic implications. We aimed to analyze comorbidity patterns in critically ill COVID-19 patients and assess their impact on in-hospital outcomes, response to treatment and sequelae.
Methods
UNASSIGNED
Multicenter prospective/retrospective observational study in intensive care units of 55 Spanish hospitals. 5866 PCR-confirmed COVID-19 patients had comorbidities recorded at hospital admission; clinical and biological parameters, in-hospital procedures and complications throughout the stay; and, clinical complications, persistent symptoms and sequelae at 3 and 6 months.
Findings
UNASSIGNED
Latent class analysis identified 3 phenotypes using training and test subcohorts: low-morbidity (n=3385; 58%), younger and with few comorbidities; high-morbidity (n=2074; 35%), with high comorbid burden; and renal-morbidity (n=407; 7%), with chronic kidney disease (CKD), high comorbidity burden and the worst oxygenation profile. Renal-morbidity and high-morbidity had more in-hospital complications and higher mortality risk than low-morbidity (adjusted HR (95% CI): 1.57 (1.34-1.84) and 1.16 (1.05-1.28), respectively). Corticosteroids, but not tocilizumab, were associated with lower mortality risk (HR (95% CI) 0.76 (0.63-0.93)), especially in renal-morbidity and high-morbidity. Renal-morbidity and high-morbidity showed the worst lung function throughout the follow-up, with renal-morbidity having the highest risk of infectious complications (6%), emergency visits (29%) or hospital readmissions (14%) at 6 months (p<0.01).
Interpretation
UNASSIGNED
Comorbidity-based phenotypes were identified and associated with different expression of in-hospital complications, mortality, treatment response, and sequelae, with CKD playing a major role. This could help clinicians in day-to-day decision making including the management of post-discharge COVID-19 sequelae.
Funding
UNASSIGNED
ISCIII, UNESPA, CIBERES, FEDER, ESF.
Identifiants
pubmed: 35655660
doi: 10.1016/j.lanepe.2022.100422
pii: S2666-7762(22)00116-8
pmc: PMC9148543
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100422Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
None declared.
Références
Circulation. 2016 Feb 9;133(6):601-9
pubmed: 26858290
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
PLoS One. 2021 Mar 31;16(3):e0248956
pubmed: 33788884
Chest. 2021 Sep;160(3):929-943
pubmed: 33964301
Am J Respir Crit Care Med. 2021 Dec 1;204(11):1274-1285
pubmed: 34543591
Lancet Infect Dis. 2021 Jun;21(6):783-792
pubmed: 33636145
Eur Respir J. 2020 May 14;55(5):
pubmed: 32269089
Respir Res. 2020 Jul 3;21(1):169
pubmed: 32620118
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
Arch Bronconeumol. 2021 Apr;57:1-2
pubmed: 34629623
Radiology. 2021 Feb;298(2):E70-E80
pubmed: 33320063
Intensive Care Med. 2020 Aug;46(8):1651-1652
pubmed: 32468086
N Engl J Med. 2021 Apr 22;384(16):1491-1502
pubmed: 33631065
Lancet Respir Med. 2021 Apr;9(4):349-359
pubmed: 33444539
Am J Respir Crit Care Med. 2020 Jul 15;202(2):219-229
pubmed: 32432483
Lancet. 2021 May 01;397(10285):1637-1645
pubmed: 33933206
JAMA Intern Med. 2021 Jan 1;181(1):41-51
pubmed: 33080002
PLoS One. 2020 May 11;15(5):e0233147
pubmed: 32392262
JAMA Intern Med. 2020 Aug 1;180(8):1081-1089
pubmed: 32396163
Crit Care. 2021 Feb 15;25(1):63
pubmed: 33588914
N Engl J Med. 2021 Nov 4;385(19):1737-1749
pubmed: 34554658
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1380-1388
pubmed: 32275452
Clin Infect Dis. 2020 Nov 19;71(16):2199-2206
pubmed: 32407459
J Clin Med. 2020 Oct 29;9(11):
pubmed: 33137919
Viruses. 2021 Mar 05;13(3):
pubmed: 33807920
JAMA Netw Open. 2021 Oct 1;4(10):e2128568
pubmed: 34643720
Ann Am Thorac Soc. 2015 Nov;12 Suppl 2:S169-75
pubmed: 26595735
Am J Respir Crit Care Med. 2020 Jun 15;201(12):1557-1559
pubmed: 32329629
Front Med (Lausanne). 2021 Jun 04;8:681336
pubmed: 34150812
Nephrol Dial Transplant. 2013 Nov;28(11):2670-7
pubmed: 23975843
Chest. 2021 Jun;159(6):2191-2204
pubmed: 33640378
Intensive Care Med. 2020 Jul;46(7):1339-1348
pubmed: 32533197
Lancet Respir Med. 2021 Dec;9(12):1377-1386
pubmed: 34653374
Chest. 2021 May;159(5):1884-1893
pubmed: 33316234
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Nat Rev Immunol. 2013 Oct;13(10):738-53
pubmed: 24037418
Respir Physiol Neurobiol. 2020 Aug;279:103455
pubmed: 32437877